Overview

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
Phase:
Phase 2
Details
Lead Sponsor:
CymaBay Therapeutics, Inc.
Treatments:
Allopurinol
Colchicine
Uric Acid